Cancer is a complex, heterogeneous disease that often transforms into therapy-resistant forms. Pharmacological agents have long been used for cancer treatment, but new approaches are required to make tumors penetrable and treatable. In this webinar, scientists will discuss how they identify and design new cell-based anticancer treatments and how they balance the need for potency with the specter of side effects.

Topics to be covered

• Cell-based immunotherapy for cancer
• Stem cells in fighting cancer
• Interdisciplinary approaches in cancer therapeutics

  • 1631639702-5d4e5a440ecf2654
    Khalid Shah, PhD
    Vice-Chair of Research, Brigham and Women's Hospital Director, Center for Stem Cell Therapeutics and Imaging, Associate Professor, Harvard Medical School Faculty, Harvard Stem Cell Institute
    Khalid Shah is the vice-chair of research at Brigham and Women's Hospital and the director of the Center for Stem Cell Therapeutics and Imaging and a principal faculty at Harvard Stem Cell Institute in Boston. In recent years, Shah and his team pioneered major developments in the cancer research field, successfully developing therapeutic stem cells for cancer, particularly brain tumors. He has received a research fellow award from the American Chemical Society, innovation awards from the James McDonnell Foundation, the Goldhirsh Foundation, and the American Association of Radiology. Shah currently holds positions on numerous councils, advisory, and editorial boards in the fields of stem cell therapy and oncology. The technologies from Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc., whose main objective is the clinical translation of therapeutic stem cells in cancer patients.